| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Research Abstract |
Japan tended to have lower dose compared to the US, whose doses were similar to that of Europe. Dose differences in Japan and the US could not be accounted for by differences in pharmacokinetics between the two regions. The dose in Japan was more likely to be same to that of the US when non-Japanese firms were the sponsors and when Japanese dose-finding study was not conducted. No relation between dose differences and drug characteristics, such therapeutic class, could be identified. Post-market safety profiles did not show any obvious differences in Japan and the US in spite of dose differences.
|
